ENZYQUEST PRIVATE COMPANY

Their core work

ENZYQUEST is a Greek biotech SME based in Heraklion, Crete, specializing in rapid molecular diagnostics and portable testing devices for infectious diseases. Their core technical expertise centers on LAMP (Loop-Mediated Isothermal Amplification) — a DNA/RNA amplification method faster and simpler than PCR that operates without laboratory infrastructure. They develop portable, field-deployable diagnostic hardware, including 3D-printed device components, designed for point-of-care use in clinical and resource-limited settings. Their disease focus spans respiratory infections (COVID-19) and vector-borne diseases (malaria), positioning them in the global health diagnostics space.

What they specialise in

How they've shifted over time

ENZYQUEST entered H2020 in 2020 with a clear applied-technology mandate: commercializing a portable LAMP-based COVID-19 diagnostic device through an Innovation Action, indicating established diagnostics capability rather than early-stage research. By 2021, they joined CypTox, a multi-year MSCA-RISE training network on next-generation insecticides targeting malaria and vector-borne disease — a shift from diagnostic hardware toward the broader infectious disease control cycle. This suggests ENZYQUEST is expanding from COVID-specific diagnostics into the tropical and neglected disease space, likely leveraging their LAMP expertise as a transferable platform for malaria detection alongside the insecticide angle of CypTox.

ENZYQUEST appears to be repositioning from a COVID-era diagnostics player toward a broader infectious disease platform company, with malaria and tropical disease as the likely next commercial focus — making them a relevant partner for global health diagnostics consortia beyond Europe.

How they like to work

ENZYQUEST has participated only as a partner in both H2020 projects and has never served as coordinator, indicating they contribute specialized technical capacity within larger programs rather than driving project strategy or administration. Despite a small project count, their consortia are notably large — 23 partners across 11 countries — which suggests they are selectively brought in as technical specialists in internationally ambitious projects. For a prospective partner, this means a responsive, focused collaborator that adds specific biotech or device expertise without competing for consortium leadership.

With 23 unique consortium partners across 11 countries from just 2 projects, ENZYQUEST participates in large, internationally diverse research networks — well above average for an SME of this size. Their geographic footprint spans at least 11 countries, consistent with projects addressing global health challenges that require cross-border clinical validation and field deployment.

What sets them apart

ENZYQUEST occupies an uncommon niche among Southern European SMEs: the combination of LAMP assay expertise with physical portable-device development (including 3D-printed components) in a single small company. Most diagnostics firms either focus on assay chemistry or device engineering — ENZYQUEST appears to bridge both. Their presence in Heraklion, Crete, within a strong university and research ecosystem (University of Crete, FORTH), likely gives them access to scientific talent and infrastructure that amplifies their capacity beyond what their headcount would suggest.

Highlights from their portfolio

• IRIS-COV
  Their flagship project — an Innovation Action (market-ready funding scheme) with EUR 285,688 in EC support, targeting commercial release of a portable COVID-19 LAMP device, signaling validated technology readiness rather than basic research.
• CypTox
  A long-running MSCA-RISE training network (2021–2025) on next-generation insecticides for malaria vector control, broadening ENZYQUEST's infectious disease portfolio beyond diagnostics into biocontrol.